Product Description
Merck was developing mk-4074, an oral ACC Inhibitor for Non-alcoholic Fatty Liver Disease
Mechanisms of Action: ACC Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Non-alcoholic Fatty Liver Disease|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MK-4074-008 | P1 |
Completed |
Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease |
2012-09-18 |